Compare Biogen Inc (BIIB) vs International Business Machines Corp (IBM) Price & Performance

Biogen (BIIB) trades at $206.48, down 0.31% on the day, with a bullish technical signal supported by moving averages. The company reported Q2 2026 EPS of $3.60, beating estimates of $2.94, and raised full-year guidance, driven by growth in Alzheimer's and rare disease portfolios. Recent acquisitions like RayThera and Apellis bolster its pipeline. Revenue for 2025 was $9.89 billion with a net income margin of 13.07%, though margins have fluctuated year-over-year.

Outlook remains positive with strong analyst support (62.5% buy rating) and a consensus price target of $234.47, implying ~14% upside. Key risks include reliance on new drug launches to offset declining multiple sclerosis sales and integration challenges from acquisitions. Cash flow trends show variability, with 2026 projecting negative net cash flow due to significant investing activities.

IBM trades at $234.91, down 0.59% today, with a mixed technical outlook showing bearish moving averages but bullish overall signals. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results pending. The company secured a $240 million AI deal with Together AI, boosting sentiment, but faces a securities fraud investigation following a 25% stock drop. Fundamentals are solid with revenue growth to $67.54 billion in 2025 and a net income margin of 15.52%, though cash flow turned negative.

Outlook is cautiously optimistic with a consensus price target of $257.38, implying 9.6% upside, supported by AI and cloud growth. Risks include the ongoing fraud probe, competitive pressures, and high debt levels. Investors should weigh strong profitability against legal and execution uncertainties in a volatile market.